Annual report
2934.TEDINET S100VB9U
Period2023-06-01 → 2024-05-31
Filed2025-02-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amends S100UXGJ. Amended by S100VBDY (2025-02-27).
Key figures · 121
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥17.7bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales |
| Revenue | ¥16.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales |
| Revenue | ¥11.9bn | 2021-06-01 → 2022-05-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥553m | 2023-06-01 → 2024-05-31 | Cons. | Operating income |
| Operating income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Operating income |
| Ordinary income | −¥643m | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥712m | 2021-06-01 → 2022-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.7bn | 2023-06-01 → 2024-05-31 | Cons. | Income before income taxes |
| Profit before tax | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥2.1bn | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥401m | 2021-06-01 → 2022-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥2.0bn | 2023-06-01 → 2024-05-31 | Cons. | Profit loss |
| Net income | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss |
| Total assets | ¥10.7bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥7.2bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥6.1bn | at 2022-05-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥9.1bn | at 2024-05-31 | Cons. | Liabilities |
| Total liabilities | ¥4.5bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.6bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥2.7bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31d | Cons. | Net assets |
| Cash and deposits | ¥1.8bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.6bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥1.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥367m | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥860m | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥3.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.6bn | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-426.06 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-410.6 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.64 | 2021-06-01 → 2022-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥86.68 | 2021-06-01 → 2022-05-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥232.55 | at 2024-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥525.78 | at 2023-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥907.43 | at 2022-05-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 10.8% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2022-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.7% | 2021-06-01 → 2022-05-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 315 | at 2024-05-31 | Cons. | Number of employees |
| Employees | 255 | at 2023-05-31 | Cons. | Number of employees |
| Employees | 278 | at 2022-05-31d | Cons. | Number of employees |
| Revenue | ¥8.1bn | 2023-06-01 → 2024-05-31 | Standalone | Net sales |
| Revenue | ¥9.4bn | 2022-06-01 → 2023-05-31 | Standalone | Net sales |
| Revenue | ¥9.3bn | 2021-06-01 → 2022-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥8.5bn | 2020-06-01 → 2021-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥7.1bn | 2019-06-01 → 2020-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥139m | 2023-06-01 → 2024-05-31 | Standalone | Operating income |
| Operating income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Operating income |
| Ordinary income | −¥219m | 2023-06-01 → 2024-05-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥724m | 2021-06-01 → 2022-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥679m | 2020-06-01 → 2021-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥174m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.9bn | 2023-06-01 → 2024-05-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Income before income taxes |
| Net income | −¥2.1bn | 2023-06-01 → 2024-05-31 | Standalone | Profit loss |
| Net income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Profit loss |
| Net income | ¥450m | 2021-06-01 → 2022-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥425m | 2020-06-01 → 2021-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥96m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥7.9bn | at 2024-05-31 | Standalone | Assets |
| Total assets | ¥5.8bn | at 2023-05-31 | Standalone | Assets |
| Total assets | ¥5.3bn | at 2022-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.6bn | at 2021-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.0bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥6.5bn | at 2024-05-31 | Standalone | Liabilities |
| Total liabilities | ¥3.1bn | at 2023-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.4bn | at 2024-05-31 | Standalone | Net assets |
| Net assets / equity | ¥2.8bn | at 2023-05-31 | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31d | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥843m | at 2020-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥657m | at 2024-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥814m | at 2023-05-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.6bn | at 2021-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥902m | at 2020-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥831m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥218m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥8m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥165m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥94m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥99m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-438.4 | 2023-06-01 → 2024-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-357.08 | 2022-06-01 → 2023-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.91 | 2021-06-01 → 2022-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥110.75 | 2020-06-01 → 2021-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.12 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥97.45 | 2021-06-01 → 2022-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥280.35 | at 2024-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥589.16 | at 2023-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥918.35 | at 2022-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥329.99 | at 2021-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥219.25 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 17.6% | at 2024-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.4% | at 2023-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.0% | at 2022-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.8% | at 2021-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.5% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 16.5% | 2021-06-01 → 2022-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 40.3% | 2020-06-01 → 2021-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 5,137,046 | at 2024-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,892,098 | at 2023-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,757,616 | at 2022-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2021-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 63 | at 2024-05-31 | Standalone | Number of employees |
| Employees | 49 | at 2023-05-31 | Standalone | Number of employees |
| Employees | 54 | at 2022-05-31d | Standalone | Number of employees |
| Employees | 46 | at 2021-05-31d | Standalone | Number of employees |
| Employees | 47 | at 2020-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 74
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-06-01 → 2024-05-31 | ¥5m |
| Reconciling Itemsreconciling | depreciation | 2023-06-01 → 2024-05-31 | ¥2m |
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2024-05-31 | −¥243m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2024-05-31 | −¥243m |
| Reconciling Itemsreconciling | segment assets | at 2024-05-31 | ¥1.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2024-05-31 | −¥588m |
| Healthcare Marketing Businessreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥418m |
| Healthcare Marketing Businessreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥10m |
| Healthcare Marketing Businessreportable segment | employees | at 2024-05-31 | 98 pure |
| Healthcare Marketing Businessreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥6.6bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥6.3bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥232m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2024-05-31 | ¥2.2bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥129m |
| Healthcare Sales Businessreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥1.5bn |
| Healthcare Sales Businessreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥3m |
| Healthcare Sales Businessreportable segment | employees | at 2024-05-31 | 76 pure |
| Healthcare Sales Businessreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥4.5bn |
| Healthcare Sales Businessreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥4.5bn |
| Healthcare Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥993,000 |
| Healthcare Sales Businessreportable segment | segment assets | at 2024-05-31 | ¥5.3bn |
| Healthcare Sales Businessreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥163m |
| Medical Care Sales Businessreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥85m |
| Medical Care Sales Businessreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥32m |
| Medical Care Sales Businessreportable segment | employees | at 2024-05-31 | 125 pure |
| Medical Care Sales Businessreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥6.8bn |
| Medical Care Sales Businessreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥6.8bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥9m |
| Medical Care Sales Businessreportable segment | segment assets | at 2024-05-31 | ¥1.9bn |
| Medical Care Sales Businessreportable segment | segment profit | 2023-06-01 → 2024-05-31 | −¥258m |
| —segment total | employees | at 2024-05-31 | 315 pure |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-06-01 → 2024-05-31 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-06-01 → 2024-05-31 | ¥45m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2024-05-31 | ¥18.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2024-05-31 | ¥17.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥243m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-05-31 | ¥9.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2024-05-31 | ¥35m |
| Reconciling Itemsreconciling | capex | 2022-06-01 → 2023-05-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2022-06-01 → 2023-05-31 | ¥765,000 |
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2023-05-31 | −¥186m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2023-05-31 | −¥186m |
| Reconciling Itemsreconciling | segment assets | at 2023-05-31 | ¥1.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2023-05-31 | −¥729m |
| Healthcare Marketing Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥4m |
| Healthcare Marketing Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥5m |
| Healthcare Marketing Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥5.2bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥5.1bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥185m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2023-05-31 | ¥1.1bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥39m |
| Healthcare Sales Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥1.1bn |
| Healthcare Sales Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥4m |
| Healthcare Sales Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥4.1bn |
| Healthcare Sales Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥4.1bn |
| Healthcare Sales Businessreportable segment | segment assets | at 2023-05-31 | ¥2.4bn |
| Healthcare Sales Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥28m |
| Medical Care Sales Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥288m |
| Medical Care Sales Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥14m |
| Medical Care Sales Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥7.7bn |
| Medical Care Sales Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥7.7bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥564,000 |
| Medical Care Sales Businessreportable segment | segment assets | at 2023-05-31 | ¥2.4bn |
| Medical Care Sales Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-06-01 → 2023-05-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-06-01 → 2023-05-31 | ¥23m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2023-05-31 | ¥17.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2023-05-31 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥186m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-05-31 | ¥5.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2023-05-31 | −¥1.1bn |
| Healthcare Marketing Businessreportable segment | employees | at 2024-05-31 | 12 pure |
| Healthcare Sales Businessreportable segment | employees | at 2024-05-31 | 22 pure |
| Medical Care Sales Businessreportable segment | employees | at 2024-05-31 | 15 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,590
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 3146 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | - | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.1125 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0082 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.2285 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.0193 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0002 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.6312 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 2369000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.4779 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 1000000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.2017 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 335400 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0677 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 131900 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0266 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 107700 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0217 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 89700 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0181 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 59000 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0119 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 42400 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0086 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 40000 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0081 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 20000 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0040 | |
| Number of shares held | CurrentYearInstant | 4195100 | |
| Shareholding ratio | CurrentYearInstant | 0.8463 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | - | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | - | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | - | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | - | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 180100 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 4953800 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 49538 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 3146 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 5137046 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 49538 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 180100 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | - | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 180100 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0351 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 180100 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | - | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 180100 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0351 | |
| Number of male directors and other officers | FilingDateInstant | 6 | |
| Number of female directors and other officers | FilingDateInstant | - |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |